Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
Casserly IP, Topol EJ, Jia G, Lange RA, Hamm C, Meier B, DiBattiste PM, Lakkis N, Chew DP, Stone GW, Cohen DJ, Moliterno DJ. Casserly IP, et al. Among authors: dibattiste pm. Am J Cardiol. 2003 Jul 15;92(2):125-9. doi: 10.1016/s0002-9149(03)00525-3. Am J Cardiol. 2003. PMID: 12860211 Clinical Trial.
Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.
Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, Neumann FJ, Robertson DH, DeLucca PT, DiBattiste PM, Gibson CM, Braunwald E; TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy)--Thrombolysis in Myocardial Infarction 18 Investigators. Cannon CP, et al. Among authors: dibattiste pm. N Engl J Med. 2001 Jun 21;344(25):1879-87. doi: 10.1056/NEJM200106213442501. N Engl J Med. 2001. PMID: 11419424 Free article. Clinical Trial.
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L; TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial. Topol EJ, et al. Among authors: dibattiste pm. N Engl J Med. 2001 Jun 21;344(25):1888-94. doi: 10.1056/NEJM200106213442502. N Engl J Med. 2001. PMID: 11419425 Free article. Clinical Trial.
Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.
Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, Robertson DH, Hille DA, DeLucca PT, DiBattiste PM, Demopoulos LA, Weintraub WS, Braunwald E; TACTICS-TIMI 18 Investigators. Morrow DA, et al. Among authors: dibattiste pm. JAMA. 2001 Nov 21;286(19):2405-12. doi: 10.1001/jama.286.19.2405. JAMA. 2001. PMID: 11712935 Clinical Trial.
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ. Stone GW, et al. Among authors: dibattiste pm. Circulation. 2002 May 21;105(20):2347-54. doi: 10.1161/01.cir.0000017635.82128.8c. Circulation. 2002. PMID: 12021219 Clinical Trial.
Comparison of degree of platelet inhibition by abciximab versus tirofiban in patients with unstable angina pectoris and non-Q-wave myocardial infarction undergoing percutaneous coronary intervention.
Herrmann HC, Swierkosz TA, Kapoor S, Tardiff DC, DiBattiste PM, Hirshfeld JW, Klugherz BD, Kolansky DM, Magness K, Valettas N, Wilensky RL. Herrmann HC, et al. Among authors: dibattiste pm. Am J Cardiol. 2002 Jun 1;89(11):1293-7. doi: 10.1016/s0002-9149(02)02329-9. Am J Cardiol. 2002. PMID: 12031731 Clinical Trial. No abstract available.
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ; TARGET Investigators. Roffi M, et al. Among authors: dibattiste pm. Circulation. 2002 Jun 11;105(23):2730-6. doi: 10.1161/01.cir.0000018123.02672.c7. Circulation. 2002. PMID: 12057986 Clinical Trial.
Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes.
Brener SJ, Murphy SA, Gibson CM, DiBattiste PM, Demopoulos LA, Cannon CP; TACTICS-TIMI 18 Investigators. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombosis in Myocardial Infarction. Brener SJ, et al. Among authors: dibattiste pm. Am J Cardiol. 2002 Sep 15;90(6):631-3. doi: 10.1016/s0002-9149(02)02569-9. Am J Cardiol. 2002. PMID: 12231091 Clinical Trial. No abstract available.
Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ; TARGET investigators. Moliterno DJ, et al. Among authors: dibattiste pm. Lancet. 2002 Aug 3;360(9330):355-60. doi: 10.1016/S0140-6736(02)09605-8. Lancet. 2002. PMID: 12241774 Clinical Trial.
59 results